Literature DB >> 34764660

In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii.

Hui Zhang1, Yunzhu Zhu1, Ning Yang1, Qinxiang Kong2, Yahong Zheng1, Na Lv1, Haoran Chen1, Chengcheng Yue1, Yanyan Liu1,3,4, Jiabin Li1,2,3,4, Ying Ye1.   

Abstract

PURPOSE: To study the in vitro and in vivo antibacterial activities of polymyxin B (PB) and other five antimicrobial agents, including imipenem (IMP), meropenem (MEM), tigecycline (TGC), sulbactam (SUL), and rifampicin (RIF), alone or in combination against carbapenem-resistant Acinetobacter baumannii (CRAB).
METHODS: Microbroth dilution method was used to determine the minimum inhibitory concentration (MIC) of ten strains of CRAB against six antibacterial drugs, and the checkerboard method was used to determine the fractional inhibitory concentration index (FICI). A mouse pneumonia model was established by intranasal instillation of Ab5075 to evaluate the antibacterial activity in vivo.
RESULTS: The resistance rate of ten CRAB strains to IMP, MEM, and SUL was 100%, that to PB and TGC was 0%, and that to RIF was 20%. When PB was used in combination with the other five antibiotics in vitro, it mainly showed synergistic and additive effects on CRAB. The synergistic effect of PB and RIF was maximal, followed by MEM and IMP but was weak with SUL and TGC. In vivo, compared to the model group (untreated with antibiotics), treatment group (six antibiotics alone and PB combined with the other five antibiotics) reduced the bacterial load in the lung tissue and the serum inflammatory factors (IL-1β, IL-6, and TNF-α). The bacterial load and the inflammatory factors of the combined group decreased significantly than that of the single group (P<0.05). The IL-6 and TNF-α values of the PB combined with the RIF group were significantly lower than the two drugs used individually.
CONCLUSION: The combination of PB and IMP, MEM, and RIF exerted robust in vitro synergistic effects on CRAB isolates. The combination of PB and the other five antimicrobial agents had a better effect in the mouse pneumonia model than single agent, while the combination of PB and RIF had the best effect.
© 2021 Zhang et al.

Entities:  

Keywords:  Acinetobacter baumannii; carbapenem-resistant; combination treatment; pneumonia infection model; polymyxin B

Year:  2021        PMID: 34764660      PMCID: PMC8577563          DOI: 10.2147/IDR.S334200

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


  32 in total

Review 1.  Antibiotic-non-antibiotic combinations for combating extremely drug-resistant Gram-negative 'superbugs'.

Authors:  Elena K Schneider; Felisa Reyes-Ortega; Tony Velkov; Jian Li
Journal:  Essays Biochem       Date:  2017-03-03       Impact factor: 8.000

2.  Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.

Authors:  John E Conte; Jeffrey A Golden; Mary Grace Kelly; Elisabeth Zurlinden
Journal:  Int J Antimicrob Agents       Date:  2005-06       Impact factor: 5.283

Review 3.  Carbapenem resistance: overview of the problem and future perspectives.

Authors:  Georgios Meletis
Journal:  Ther Adv Infect Dis       Date:  2016-02

4.  Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.

Authors:  Ronald N Jones; Mary Jane Ferraro; L Barth Reller; Paul C Schreckenberger; Jana M Swenson; Helio S Sader
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

5.  Acid aspiration provokes the pneumonia caused by multidrug-resistant Acinetobacter baumannii in BALB/c mice.

Authors:  Shyh-Ren Chiang; Hung-Jen Tang; Chung-Hua Chen; Chi-Chung Chen; Wen-Ying Lee; Ping-Chin Chang; Yu-Hsin Chiu; Yin-Ching Chuang
Journal:  Int J Infect Dis       Date:  2013-03-20       Impact factor: 3.623

Review 6.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 7.  Tigecycline pharmacokinetic/pharmacodynamic update.

Authors:  Alasdair P MacGowan
Journal:  J Antimicrob Chemother       Date:  2008-09       Impact factor: 5.790

Review 8.  The emergence of clinical resistance to tigecycline.

Authors:  Yan Sun; Yun Cai; Xu Liu; Nan Bai; Beibei Liang; Rui Wang
Journal:  Int J Antimicrob Agents       Date:  2012-11-03       Impact factor: 5.283

9.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Authors:  Mical Paul; George L Daikos; Emanuele Durante-Mangoni; Dafna Yahav; Yehuda Carmeli; Yael Dishon Benattar; Anna Skiada; Roberto Andini; Noa Eliakim-Raz; Amir Nutman; Oren Zusman; Anastasia Antoniadou; Pia Clara Pafundi; Amos Adler; Yaakov Dickstein; Ioannis Pavleas; Rosa Zampino; Vered Daitch; Roni Bitterman; Hiba Zayyad; Fidi Koppel; Inbar Levi; Tanya Babich; Lena E Friberg; Johan W Mouton; Ursula Theuretzbacher; Leonard Leibovici
Journal:  Lancet Infect Dis       Date:  2018-02-16       Impact factor: 25.071

10.  Colistin susceptibility testing by Etest and disk diffusion methods.

Authors:  Irene Galani; Flora Kontopidou; Maria Souli; Panagiota-Danai Rekatsina; Evangelos Koratzanis; John Deliolanis; Helen Giamarellou
Journal:  Int J Antimicrob Agents       Date:  2008-03-06       Impact factor: 5.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.